about
The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells.Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention.Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention.MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotypeEnhanced regulation of cell cycle and suppression of osteoblast differentiation molecular signatures by prostate cancer stem-like holoclones.Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLCCD10-/ALDH- cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy.MyD88 is an essential component of retinoic acid-induced differentiation in human pluripotent embryonal carcinoma cells.
P50
Q33825555-7F33B9F6-CE04-456E-9C2B-9278F2919786Q34056033-E0B22F94-AA90-4E58-BCD8-B068B032FD05Q34968735-B9C2DB51-4728-4458-ABA5-7034493B0DD2Q37661508-84C05142-398A-4EDC-9048-EF7A6C3ECB06Q37706921-A6BF3F13-D10E-4CAB-AF4F-FE1216A89A06Q38868077-CDF5E73F-B102-4B44-BCCC-685E796F3C19Q42700773-DA3AE3DA-671D-4DDF-92C8-871BCEC8523CQ45046872-3274FCCD-E707-428B-A303-09AA6D96AF4DQ47699244-0067B4AB-669E-4C33-8C5D-9BBCE707B0F7
P50
description
medical researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Brendan Ffrench
@ast
Brendan Ffrench
@en
Brendan Ffrench
@es
Brendan Ffrench
@nl
type
label
Brendan Ffrench
@ast
Brendan Ffrench
@en
Brendan Ffrench
@es
Brendan Ffrench
@nl
prefLabel
Brendan Ffrench
@ast
Brendan Ffrench
@en
Brendan Ffrench
@es
Brendan Ffrench
@nl
P106
P31
P496
0000-0002-5647-3734